Genetic Disorders Market is expected to register a healthy CAGR of 13.68% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the focus of various pharmaceutical organizations on development of specialized therapies for treatment of genetic disorders. Some are the key players taken under coverage for this study are Amicus Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Vertex Pharmaceuticals Incorporated; F. Hoffmann-La Roche Ltd; Abbott; Amgen Inc.; ELITechGroup; GW Pharmaceuticals plc; Thermo Fisher Scientific Inc.; Pfizer Inc.; PerkinElmer Inc.; AutoGenomics; Bio-Rad Laboratories, Inc.; BioMarin; Sarepta Therapeutics among others.

Click to Get Global Genetic Disorders Market Research Sample PDF Copy Here @ 

Data Bridge Market Research released a new market study on Global Genetic Disorders Market with market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data.

Market Definition: Global Genetic Disorders Market

Genetic disorders inherited disorders that are passed onto the next-generation by gene transferring from one generation to the others. These disorders are highly complicated and rare to treat and require specialized treatments/therapeutics for their improvements and reduced prevalence amongst patients. These disorders are generally characterized as life-threating and are progressive in nature with each disease carrying different symptoms. Currently, the pipeline for treatment of these disorders is abundant with a number of therapeutics currently in the late-stage of their trials.

Market Drivers

  • Prevailing cases of genetic and chronic disease along with the increasing government initiatives in creating awareness regarding the genetic test and diagnosis; acts as a driver for the growth of this market
  • Significant volume and strength of pipeline drugs and therapies for genetic disorders; this factor is expected to boost the growth of the market
  • Increasing technological advancement and R&D funding is another factor which will surge the market growth
  • Increasing prevalence of drugs being approved in the recent years along with various drugs entering their last or late-stage of development; this factor is expected to propel the growth of the market

Market Restraints

  • Significant prevalence and attrition towards reduction of drugs in clinical trial for genetic disorders; this factor is expected to hinder the growth of the market
  • High costs associated with the diagnosis and identification of genetic disorders can restrict the market growth
  • Complications related to social and ethical categories with the utilization of genetic testing; this factor is expected to act as a restraint in the market growth

Segmentation: Global Genetic Disorders Market

By Indication

  • Cystic Fibrosis (CF)
  • Duchenne Muscular Dystrophy (DMD)
  • Lysosomal Storage Disease (LSD)
  • Paraoxysmal Nocturnal Hemoglobinuria (PNH)

By Disease Type

  • Alzheimer’s Disease
  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Duchenne Muscular Dystrophy (DMD)
  • Thalassemia
  • Huntington’s Disease
  • Rare Diseases
  • Others

By Geography

  • North America
  • Europe
    • Germany
    • Italy
    • U.K.
    • France
    • Spain
    • Netherlands
    • Belgium
    • Switzerland
    • Turkey
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Singapore
    • Malaysia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Rest of South America
  • Middle East and Africa
    • South Africa
    • Rest of Middle East and Africa

Order a Copy of This Research Report @

Key Developments in the Market:

  • In June 2019, Vertex Pharmaceuticals Incorporated announced that they had expanded their gene editing capabilities for the development of novel therapies in Duchenne Muscular Dystrophy (DMD) and Myotonic Dystotrophy Type 1 (DM1) with the help of an expansion on the existing collaboration with CRISPR Therapeutics along with the acquisition of Exonics Therapeutics
  • In August 2018, U.S. FDA announced that they had approved “Galafold (migalastat)”, first approved oral medication for the treatment of “Fabry” disease having a genetic mutation responsive towards treatment with “Galafold”. The U.S. FDA has granted the approval for the drug to Amicus Therapeutics, Inc. having received accelerated approval pathway with the most extreme reactions against the drug being headache, throat & nasal irritation, fever, nausea and urinary tract infection

Competitive Analysis:

Global genetic disorders market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of genetic disorders market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global genetic disorders market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Get Full TOC @

Source link